Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-0.15%
SPX
+0.04%
IXIC
+0.36%
FTSE
-2.03%
N225
-3.06%
AXJO
-1.34%
Cashu Logo
⌘K
Log In
HomeWatchlistNewsSignals
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Stocks
Information Technology
fkwl
Franklin Wireless
NASDAQ: FKWL
-0.09 (-2.32%)
3.86
USD
At close at Mar 02, 21:38 UTC
Summary
News
Signals
Benchmarks
Financials
Join our newsletter to keep up to date with us!

RFU Receives NIH Grant for Groundbreaking Research on Calcium Channels in Neurological Disorders

publisher logo
Cashu
about 1 month ago
Cashu TLDR
  • Dr. Hongkyun Kim at RFU receives a $1.9 million NIH grant for research on calcium channels.
  • His research focuses on CaV2 channels, critical for neuronal communication and linked to neurological disorders.
  • RFU aims to enhance health sciences through innovative research, honoring the legacy of Dr. Rosalind Franklin.
FKWL
Franklin Wireless
-2.32%

Groundbreaking Research on Calcium Channels at Rosalind Franklin University

Rosalind Franklin University (RFU) in North Chicago embarks on a significant advancement in neuroscience with the recent announcement that Dr. Hongkyun Kim has secured a substantial five-year grant from the National Institutes of Health (NIH). The grant, totaling $1,911,417, will enable Dr. Kim, a dedicated professor in the Center for Cancer Cell Biology, Immunology, and Infection, to conduct pioneering research on the molecular and cellular regulation of CaV2 voltage-gated calcium channels. These channels are essential for synaptic transmission and play a critical role in neuronal communication, making them a focal point in understanding various neurological disorders.

Dr. Kim’s research aims to unravel the complexities surrounding the dysregulation of CaV2 channels, a phenomenon often associated with conditions such as epilepsy, migraines, and chronic pain. By employing genetic and genomic methods, Dr. Kim seeks to identify the molecular components that regulate the abundance of these calcium channels, utilizing C. elegans as a model organism for his studies. His innovative approach is expected to provide deeper insights into how these channels function and contribute to disease pathology, potentially leading to new therapeutic avenues for individuals suffering from neurological disorders.

Joseph DiMario, RFU's executive vice president for research, commends Dr. Kim for his extensive contributions to the field, noting that this NIH award not only recognizes his expertise but also underscores the university's commitment to enhancing the understanding of critical biological mechanisms. RFU, known for its focus on health and biomedical education, continues to foster research that aligns with its mission to improve wellness and train future health professionals. The institution's efforts in neuroscience and brain-related diseases reflect the legacy of its namesake, Dr. Rosalind Franklin, who exemplified a spirit of inquiry and innovation.

In addition to this significant research funding, RFU remains dedicated to its core mission of education and research. The university comprises several colleges, including the Chicago Medical School and the College of Pharmacy, which collectively contribute to its reputation as a leader in health sciences. With the support of grants like the one awarded to Dr. Kim, RFU continues to position itself at the forefront of biomedical research, working tirelessly to address pressing health challenges faced by society.

This latest development not only promises to advance scientific knowledge but also highlights the important role of academic institutions in driving research that can lead to impactful health solutions. As RFU progresses with Dr. Kim’s groundbreaking work, the potential for improved treatments for neurological disorders becomes increasingly tangible.

The content provided here is for informational purposes only and should not be considered financial or investment advice. Investing in stocks carries risks, including potential loss of principal. Always do your own research and consult with a licensed financial advisor before making any investment decisions. We are not responsible for any losses or damages resulting from your use of this information.

More News

Feature in Progress
This section is under development. Check back soon for updates!